Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Case Report

Published on 11 Aug 2026

Case Report: Low-dose mitotane in a case of recurrent adrenocortical carcinoma: a 20-year clinical perspective

in Pharmacology of Anti-Cancer Drugs

Tomasz Buczek
Ewa Kilar-Kobierzycka
Jowita Halupczok-Żyła
Marek Bolanowski

Frontiers in Oncology

doi 10.3389/fonc.2026.1826235

274 views

Case Report

Published on 06 Aug 2026

Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20–mutant NSCLC: case report

in Pharmacology of Anti-Cancer Drugs

Basil Dabbah
Roni Gillis
Jaber Salim
Adar Yaacov
Bar Cohen
Areen Abu Remilah
Yehonatan Turner
Noam Asna
Nir Peled

Frontiers in Oncology

doi 10.3389/fonc.2026.1812440

1,172 views

Original Research

Published on 05 Aug 2026

Risk factors for irinotecan-induced hepatotoxicity: a retrospective cohort study

in Pharmacology of Anti-Cancer Drugs

Fatemah A. Alherz
Anwar M. Alnakhli
Aisha M. Alqarni
Alanoud F. Alshammari
Alhanouf M. Ruwayi
Rahaf M. Alyamani
Haya Al-salloum
Mohammad J. Al-Yamani
Farag Shuweihdi

Frontiers in Oncology

doi 10.3389/fonc.2026.1777922

268 views

Case Report

Published on 31 Jul 2026

Case Report: Diabetic ketoacidosis following EGFR-TKIs therapy via aggravated insulin resistance

in Pharmacology of Anti-Cancer Drugs

Shengjie Wu
Li Jing
Yan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2026.1862643

326 views

Review

Published on 31 Jul 2026

Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation

in Pharmacology of Anti-Cancer Drugs

Xin Wang
ZhuYong Li
Bin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2026.1821922

374 views

Original Research

Accepted on 29 Jul 2026

Indole-3-Acetic Acid-Derived Carbon Dots Inhibit the Malignant Progression of Colorectal Cancer via Negative Regulation of the MAPK/ERK Pathway

in Pharmacology of Anti-Cancer Drugs

Rui Li
Wenqiang Li
Wenyue Ma
Xiaohui Dou
Fulong Ji
Daqing Sun

Frontiers in Oncology

168 views

Case Report

Published on 27 Jul 2026

Small intestine choriocarcinoma with brain, lung and liver metastases in a male patient: a case report

in Pharmacology of Anti-Cancer Drugs

Huamei Xu
Dayou Shi
Chuan Wang
Qingling Hua
Xiuling Wu

Frontiers in Oncology

doi 10.3389/fonc.2026.1874971

360 views

Original Research

Published on 27 Jul 2026

Prospective evaluation of dynamic changes in L3 skeletal muscle index and chemotherapy-induced peripheral neuropathy during albumin-bound paclitaxel chemotherapy

in Pharmacology of Anti-Cancer Drugs

Meijin Yue
Shuqin Deng
Gaowa Daleng
Feng Chen
Jun Zhao
Ying Jiang
Jiaxuan Li
Jiayuan Guo
Yalong Han
Zhengyu Li

Frontiers in Oncology

doi 10.3389/fonc.2026.1844651

426 views

Original Research

Accepted on 24 Jul 2026

MiR-150-5p suppresses high-grade transformation of lacrimal adenoid cystic carcinoma by downregulating COL1A1

in Pharmacology of Anti-Cancer Drugs

Xiaoyu Zhu
Jinjie Liu
Meixia Jiang
Xun Liu
Shuang Chen
Tingting Lin
Limin Zhu

Frontiers in Oncology

187 views

Original Research

Published on 23 Jul 2026

Development and characterization of an injectable thermoresponsive PLGA nanoparticle-loaded in situ gel for sustained exemestane delivery

in Pharmacology of Anti-Cancer Drugs

Priya Singh
Namrata Swain
Shagufa Shamim
Vemuri Sai Phanindra
Sruti Sikha Dikhit

Frontiers in Oncology

doi 10.3389/fonc.2026.1905253

530 views

Mini Review

Published on 14 Jul 2026

Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations

in Pharmacology of Anti-Cancer Drugs

Wei Li
Hui Xu

Frontiers in Oncology

doi 10.3389/fonc.2026.1864260

511 views

Editorial

Published on 03 Jul 2026

Editorial: Advancement of chemotherapy in breast cancer: predictive markers, resistance mechanism and therapeutic strategies

in Pharmacology of Anti-Cancer Drugs

Richard Beatson
Jinhai Deng
Teng Pan
Zhendong Shi
Ming Zhao

Frontiers in Oncology

doi 10.3389/fonc.2026.1896583

887 views

Case Report

Published on 29 Jun 2026

Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report

in Pharmacology of Anti-Cancer Drugs

Liping Sun
Juan Lang
Weiying Zhang
Zhongkui Xiong

Frontiers in Oncology

doi 10.3389/fonc.2026.1850680

947 views

Editorial

Published on 22 Jun 2026

Editorial: Precision oncology: integrating molecular mechanisms, organoid models, and omics technologies for personalized cancer care

in Pharmacology of Anti-Cancer Drugs

Muharrem Okan Cakir
Betul Karademir-Yilmaz
G. Hossein Ashrafi
Mustafa Özdoğan

Frontiers in Oncology

doi 10.3389/fonc.2026.1898081

601 views

Review

Published on 17 Jun 2026

Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance

in Pharmacology of Anti-Cancer Drugs

Maliheh Hasannia
Mahdi Abounoori
Fatemeh Mahmoudian
Maryam Shirzad
Abbas Rahdar
Selamu Duguna
Sadanand Pandey

Frontiers in Oncology

doi 10.3389/fonc.2026.1812990

1,426 views
1 citation

Original Research

Published on 17 Jun 2026

Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma

in Pharmacology of Anti-Cancer Drugs

Zhan Wang
Ze Zhao
Yang Yang
Yi Zhao

Frontiers in Oncology

doi 10.3389/fonc.2026.1856255

845 views

Original Research

Published on 15 Jun 2026

Dose rounding of trastuzumab deruxtecan in chinese patients: cost savings and safety outcomes in real-world study

in Pharmacology of Anti-Cancer Drugs

Haochun Tang
Ziying Li
Ziyuan Zhou
Lingzhi Ren
Chengsheng Xie
Jun Meng
Guohui Li

Frontiers in Oncology

doi 10.3389/fonc.2026.1868388

864 views

Brief Research Report

Published on 10 Jun 2026

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma

in Pharmacology of Anti-Cancer Drugs

Joseph B. Parker
Richard W. Joseph
Vera J. Suman
Yiyi Yan
Ruqin Chen

Frontiers in Oncology

doi 10.3389/fonc.2026.1797703

1,767 views

Original Research

Published on 10 Jun 2026

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib

in Pharmacology of Anti-Cancer Drugs

Lisa Heß
Jule Koch
Finja Göttsche
Thomas Reinheckel

Frontiers in Oncology

doi 10.3389/fonc.2026.1845048

1,108 views

Case Report

Published on 10 Jun 2026

Case Report: Fatal pneumonitis caused by Camrelizumab and Erlotinib in a patient with metastatic pancreatic cancer

in Pharmacology of Anti-Cancer Drugs

Yanyan Jiang
Lihong Ma
Bei Lu
Wei Tian

Frontiers in Oncology

doi 10.3389/fonc.2026.1746639

853 views

Editorial

Published on 27 May 2026

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III

in Pharmacology of Anti-Cancer Drugs

Yan Zhang
Leilei Fu
Yinu Wang

Frontiers in Oncology

doi 10.3389/fonc.2026.1875555

2,622 views

Brief Research Report

Published on 22 May 2026

ACSL4-driven ferroptosis susceptibility as a targetable vulnerability in monocytic acute myeloid leukemia

in Pharmacology of Anti-Cancer Drugs

Federico De Marchi
Michele Gottardi

Frontiers in Oncology

doi 10.3389/fonc.2026.1837940

1,501 views
1 citation

Original Research

Published on 21 May 2026

A meta-analysis on the effectiveness and safety of FOLFOX plus bevacizumab for colorectal cancer treatment

in Pharmacology of Anti-Cancer Drugs

Weiyin Ma
Zhengming Song
Yuandong Zhu

Frontiers in Oncology

doi 10.3389/fonc.2026.1834867

1,173 views

Original Research

Published on 15 May 2026

Predicting the efficacy of recombinant human thrombopoietin in treating cancer therapy-related thrombocytopenia: based on stacking ensemble methods

in Pharmacology of Anti-Cancer Drugs

Kun Hou
Rui Huangfu
Zhijuan Guo
Yan Gao
Haiwen Lu
Zhongwu Li
Zhenfei Wang

Frontiers in Oncology

doi 10.3389/fonc.2026.1751214

1,449 views

1,190 articles

articles

Case Report: Low-dose mitotane in a case of recurrent adrenocortical carcinoma: a 20-year clinical perspective

Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20–mutant NSCLC: case report

Risk factors for irinotecan-induced hepatotoxicity: a retrospective cohort study

Case Report: Diabetic ketoacidosis following EGFR-TKIs therapy via aggravated insulin resistance

Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation

Indole-3-Acetic Acid-Derived Carbon Dots Inhibit the Malignant Progression of Colorectal Cancer via Negative Regulation of the MAPK/ERK Pathway

Small intestine choriocarcinoma with brain, lung and liver metastases in a male patient: a case report

Prospective evaluation of dynamic changes in L3 skeletal muscle index and chemotherapy-induced peripheral neuropathy during albumin-bound paclitaxel chemotherapy

MiR-150-5p suppresses high-grade transformation of lacrimal adenoid cystic carcinoma by downregulating COL1A1

Development and characterization of an injectable thermoresponsive PLGA nanoparticle-loaded in situ gel for sustained exemestane delivery

Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations

Editorial: Advancement of chemotherapy in breast cancer: predictive markers, resistance mechanism and therapeutic strategies

Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report

Editorial: Precision oncology: integrating molecular mechanisms, organoid models, and omics technologies for personalized cancer care

Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance

Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma

Dose rounding of trastuzumab deruxtecan in chinese patients: cost savings and safety outcomes in real-world study

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib

Case Report: Fatal pneumonitis caused by Camrelizumab and Erlotinib in a patient with metastatic pancreatic cancer

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III

ACSL4-driven ferroptosis susceptibility as a targetable vulnerability in monocytic acute myeloid leukemia

A meta-analysis on the effectiveness and safety of FOLFOX plus bevacizumab for colorectal cancer treatment

Predicting the efficacy of recombinant human thrombopoietin in treating cancer therapy-related thrombocytopenia: based on stacking ensemble methods